Aap Implantate AG Achieves Financial Milestones in 2024

aap Implantate AG successfully closed the 2024 financial year, reporting positive developments despite economic challenges. The company published its HGB financial statements with an unqualified auditor's opinion and released preliminary unaudited group figures on its website. The Group's EBITDA improved significantly from EUR -3.4 million to EUR -0.85 million, thanks to effective cost control and strategic investments.

Sales grew by 6% to EUR 12.2 million, aligning with the trauma market average. Strong performances were noted in the EMEA and LATAM regions, with Spain/Portugal growing by 32% and South Africa by 51%. The LATAM core markets, Mexico and Brazil, posted double-digit growth, driven by distributor investments.

The APAC region, particularly Thailand, demonstrated robust performance with a 43% year-on-year growth. New markets in Taiwan, Malaysia, and South Korea contributed to regional expansion. The company's gross margin rose to 87%, reflecting a strong demand for its high-quality products. Significant achievements included MDR certification and the approval of the HBS screw system in the US, enhancing operational stability and market opportunities. With 2025 showing a promising start, the company predicts sales between EUR 12.0 million and EUR 14.0 million alongside noteworthy EBITDA figures.